Literature DB >> 25976083

Insights into bombesin receptors and ligands: Highlighting recent advances.

Irene Ramos-Álvarez1, Paola Moreno1, Samuel A Mantey1, Taichi Nakamura1, Bernardo Nuche-Berenguer1, Terry W Moody2, David H Coy3, Robert T Jensen4.   

Abstract

This following article is written for Prof. Abba Kastin's Festschrift, to add to the tribute to his important role in the advancement of the role of peptides in physiological, as well as pathophysiological processes. There have been many advances during the 35 years of his prominent role in the Peptide field, not only as editor of the journal Peptides, but also as a scientific investigator and editor of two volumes of the Handbook of Biological Active Peptides [146,147]. Similar to the advances with many different peptides, during this 35 year period, there have been much progress made in the understanding of the pharmacology, cell biology and the role of (bombesin) Bn receptors and their ligands in various disease states, since the original isolation of bombesin from skin of the European frog Bombina bombina in 1970 [76]. This paper will briefly review some of these advances over the time period of Prof. Kastin 35 years in the peptide field concentrating on the advances since 2007 when many of the results from earlier studies were summarized [128,129]. It is appropriate to do this because there have been 280 articles published in Peptides during this time on bombesin-related peptides and it accounts for almost 5% of all publications. Furthermore, 22 Bn publications we have been involved in have been published in either Peptides [14,39,55,58,81,92,93,119,152,216,225,226,231,280,302,309,355,361,362] or in Prof. Kastin's Handbook of Biological Active Peptides [137,138,331]. Published by Elsevier Inc.

Entities:  

Keywords:  Bombesin; Gastrin releasing peptide; Neuromedin b; Obesity; Pruritus

Mesh:

Substances:

Year:  2015        PMID: 25976083      PMCID: PMC4641779          DOI: 10.1016/j.peptides.2015.04.026

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  387 in total

1.  Peptide modified nanocarriers for selective targeting of bombesin receptors.

Authors:  Antonella Accardo; Rosalba Mansi; Anna Morisco; Gaetano Mangiapia; Luigi Paduano; Diego Tesauro; Aurel Radulescu; Michela Aurilio; Luigi Aloj; Claudio Arra; Giancarlo Morelli
Journal:  Mol Biosyst       Date:  2010-02-09

2.  Gastrin-releasing peptide receptor (GRPR) mediates chemotaxis in neutrophils.

Authors:  Rafael Sanguinetti Czepielewski; Bárbara Nery Porto; Lucas Bortolotto Rizzo; Rafael Roesler; Ana Lúcia Abujamra; Larissa Garcia Pinto; Gilberto Schwartsmann; Fernando de Queiroz Cunha; Cristina Bonorino
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-27       Impact factor: 11.205

3.  Rational design of a peptide agonist that interacts selectively with the orphan receptor, bombesin receptor subtype 3.

Authors:  S A Mantey; D H Coy; T K Pradhan; H Igarashi; I M Rizo; L Shen; W Hou; S J Hocart; R T Jensen
Journal:  J Biol Chem       Date:  2000-12-08       Impact factor: 5.157

Review 4.  Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy.

Authors:  D B Cornelio; R Roesler; G Schwartsmann
Journal:  Ann Oncol       Date:  2007-03-09       Impact factor: 32.976

5.  Site-specific effects of gastrin-releasing peptide in the suprachiasmatic nucleus.

Authors:  George J Kallingal; Eric M Mintz
Journal:  Eur J Neurosci       Date:  2013-10-28       Impact factor: 3.386

6.  The gastrin-releasing peptide receptor is rapidly phosphorylated by a kinase other than protein kinase C after exposure to agonist.

Authors:  G S Kroog; E Sainz; P J Worland; M A Akeson; R V Benya; R T Jensen; J F Battey
Journal:  J Biol Chem       Date:  1995-04-07       Impact factor: 5.157

7.  Target selective micelles for bombesin receptors incorporating Au(III)-dithiocarbamato complexes.

Authors:  Paola Ringhieri; Roberta Iannitti; Chiara Nardon; Rosanna Palumbo; Dolores Fregona; Giancarlo Morelli; Antonella Accardo
Journal:  Int J Pharm       Date:  2014-07-08       Impact factor: 5.875

8.  Functional properties of two bombesin-like peptide receptors revealed by the analysis of mice lacking neuromedin B receptor.

Authors:  H Ohki-Hamazaki; Y Sakai; K Kamata; H Ogura; S Okuyama; K Watase; K Yamada; K Wada
Journal:  J Neurosci       Date:  1999-02-01       Impact factor: 6.167

9.  Minimal ligand analysis of gastrin releasing peptide. Receptor binding and mitogenesis.

Authors:  D C Heimbrook; M E Boyer; V M Garsky; N L Balishin; D M Kiefer; A Oliff; M W Riemen
Journal:  J Biol Chem       Date:  1988-05-25       Impact factor: 5.157

10.  Multifunctional targeted therapy system based on (99m) Tc/(177) Lu-labeled gold nanoparticles-Tat(49-57)-Lys(3) -bombesin internalized in nuclei of prostate cancer cells.

Authors:  Nallely Jiménez-Mancilla; Guillermina Ferro-Flores; Clara Santos-Cuevas; Blanca Ocampo-García; Myrna Luna-Gutiérrez; Erika Azorín-Vega; Keila Isaac-Olivé; Miguel Camacho-López; Eugenio Torres-García
Journal:  J Labelled Comp Radiopharm       Date:  2013-07-19       Impact factor: 1.921

View more
  38 in total

Review 1.  Radiolabeled bombesin derivatives for preclinical oncological imaging.

Authors:  Carolina de Aguiar Ferreira; Leonardo Lima Fuscaldi; Danyelle M Townsend; Domenico Rubello; André Luís Branco de Barros
Journal:  Biomed Pharmacother       Date:  2016-12-29       Impact factor: 6.529

Review 2.  Bombesin receptor subtype 3 as a potential target for obesity and diabetes.

Authors:  Nieves González; Paola Moreno; Robert T Jensen
Journal:  Expert Opin Ther Targets       Date:  2015-06-12       Impact factor: 6.902

3.  Immediate Release of Gastrin-Releasing Peptide Mediates Delayed Radiation-Induced Pulmonary Fibrosis.

Authors:  Robert M Tighe; Karissa Heck; Erik Soderblom; Shutang Zhou; Anastasiya Birukova; Kenneth Young; Douglas Rouse; Jessica Vidas; Miglena K Komforti; Christopher B Toomey; Frank Cuttitta; Mary E Sunday
Journal:  Am J Pathol       Date:  2019-03-18       Impact factor: 4.307

4.  Development and Characterization of a Novel, High-Affinity, Specific, Radiolabeled Ligand for BRS-3 Receptors.

Authors:  Irene Ramos-Alvarez; Lingaku Lee; Samuel A Mantey; Robert T Jensen
Journal:  J Pharmacol Exp Ther       Date:  2019-04-10       Impact factor: 4.030

Review 5.  Bombesin related peptides/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment.

Authors:  Paola Moreno; Irene Ramos-Álvarez; Terry W Moody; Robert T Jensen
Journal:  Expert Opin Ther Targets       Date:  2016-03-28       Impact factor: 6.902

6.  Molecular basis for high affinity and selectivity of peptide antagonist, Bantag-1, for the orphan BB3 receptor.

Authors:  Taichi Nakamura; Irene Ramos-Álvarez; Tatiana Iordanskaia; Paola Moreno; Samuel A Mantey; R T Jensen
Journal:  Biochem Pharmacol       Date:  2016-06-23       Impact factor: 5.858

Review 7.  Trends in GPCR drug discovery: new agents, targets and indications.

Authors:  Alexander S Hauser; Misty M Attwood; Mathias Rask-Andersen; Helgi B Schiöth; David E Gloriam
Journal:  Nat Rev Drug Discov       Date:  2017-10-27       Impact factor: 84.694

Review 8.  Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer.

Authors:  Terry W Moody; Bernardo Nuche-Berenguer; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2016-02       Impact factor: 3.243

9.  Novel chiral-diazepines function as specific, selective receptor agonists with variable coupling and species variability in human, mouse and rat BRS-3 receptor cells.

Authors:  Irene Ramos-Álvarez; Taichi Nakamura; Samuel A Mantey; Paola Moreno; Bernardo Nuche-Berenguer; Robert T Jensen
Journal:  Peptides       Date:  2015-10-31       Impact factor: 3.750

10.  A possible new target in lung-cancer cells: The orphan receptor, bombesin receptor subtype-3.

Authors:  Paola Moreno; Samuel A Mantey; Suk H Lee; Irene Ramos-Álvarez; Terry W Moody; Robert T Jensen
Journal:  Peptides       Date:  2018-02-02       Impact factor: 3.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.